Literature DB >> 24282356

Diagnosis of IgG4-related sclerosing cholangitis.

Takahiro Nakazawa1, Itaru Naitoh, Kazuki Hayashi, Katsuyuki Miyabe, Shuya Simizu, Takashi Joh.   

Abstract

IgG4-related sclerosing cholangitis (IgG4-SC) is often associated with autoimmune pancreatitis. However, the diffuse cholangiographic abnormalities observed in IgG4-SC may resemble those observed in primary sclerosing cholangitis (PSC), and the presence of segmental stenosis suggests cholangiocarcinoma (CC). IgG4-SC responds well to steroid therapy, whereas PSC is only effectively treated with liver transplantation and CC requires surgical intervention. Since IgG4-SC was first described, it has become a third distinct clinical entity of sclerosing cholangitis. The aim of this review was to introduce the diagnostic methods for IgG4-SC. IgG4-SC should be carefully diagnosed based on a combination of characteristic clinical, serological, morphological, and histopathological features after cholangiographic classification and targeting of a disease for differential diagnosis. When intrapancreatic stenosis is detected, pancreatic cancer or CC should be ruled out. If multiple intrahepatic stenoses are evident, PSC should be distinguished on the basis of cholangiographic findings and liver biopsy with IgG4 immunostaining. Associated inflammatory bowel disease is suggestive of PSC. If stenosis is demonstrated in the hepatic hilar region, CC should be discriminated by ultrasonography, intraductal ultrasonography, bile duct biopsy, and a higher cutoff serum IgG4 level of 182 mg/dL.

Entities:  

Keywords:  IgG4; IgG4-related sclerosing cholangitis; Primary sclerosing cholangitis; Sclerosing cholangitis

Mesh:

Substances:

Year:  2013        PMID: 24282356      PMCID: PMC3837265          DOI: 10.3748/wjg.v19.i43.7661

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  54 in total

1.  Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012.

Authors:  Hirotaka Ohara; Kazuichi Okazaki; Hirohito Tsubouchi; Kazuo Inui; Shigeyuki Kawa; Terumi Kamisawa; Susumu Tazuma; Kazushige Uchida; Kenji Hirano; Hitoshi Yoshida; Takayoshi Nishino; Shigeru B H Ko; Nobumasa Mizuno; Hideaki Hamano; Atsushi Kanno; Kenji Notohara; Osamu Hasebe; Takahiro Nakazawa; Yasuni Nakanuma; Hajime Takikawa
Journal:  J Hepatobiliary Pancreat Sci       Date:  2012-09       Impact factor: 7.027

2.  Comparison of steroid pulse therapy and conventional oral steroid therapy as initial treatment for autoimmune pancreatitis.

Authors:  Takashi Tomiyama; Kazushige Uchida; Mitsunobu Matsushita; Tsukasa Ikeura; Toshiro Fukui; Makoto Takaoka; Akiyoshi Nishio; Kazuichi Okazaki
Journal:  J Gastroenterol       Date:  2010-12-25       Impact factor: 7.527

3.  Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis.

Authors:  Hitoshi Sano; Takahiro Nakazawa; Tomoaki Ando; Kazuki Hayashi; Itaru Naitoh; Fumihiro Okumura; Katsuyuki Miyabe; Michihiro Yoshida; Satoru Takahashi; Hirotaka Ohara; Takashi Joh
Journal:  J Hepatobiliary Pancreat Sci       Date:  2011-03       Impact factor: 7.027

4.  Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma.

Authors:  Abdul M Oseini; Roongruedee Chaiteerakij; Abdirashid M Shire; Amaar Ghazale; Joseph Kaiya; Catherine D Moser; Ileana Aderca; Teresa A Mettler; Terry M Therneau; Lizhi Zhang; Naoki Takahashi; Suresh T Chari; Lewis R Roberts
Journal:  Hepatology       Date:  2011-08-08       Impact factor: 17.425

Review 5.  Sclerosing cholangitis: a focus on secondary causes.

Authors:  Rupert Abdalian; E Jenny Heathcote
Journal:  Hepatology       Date:  2006-11       Impact factor: 17.425

6.  High serum IgG4 concentrations in patients with sclerosing pancreatitis.

Authors:  H Hamano; S Kawa; A Horiuchi; H Unno; N Furuya; T Akamatsu; M Fukushima; T Nikaido; K Nakayama; N Usuda; K Kiyosawa
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

7.  Cholangiography can discriminate sclerosing cholangitis with autoimmune pancreatitis from primary sclerosing cholangitis.

Authors:  Takahiro Nakazawa; Hirotaka Ohara; Hitoshi Sano; Shigeru Aoki; Shinya Kobayashi; Tetsu Okamoto; Hideto Imai; Tomoyuki Nomura; Takashi Joh; Makoto Itoh
Journal:  Gastrointest Endosc       Date:  2004-12       Impact factor: 9.427

8.  IgG4-related sclerosing cholangitis with and without hepatic inflammatory pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis: do they belong to a spectrum of sclerosing pancreatitis?

Authors:  Yoh Zen; Kenichi Harada; Motoko Sasaki; Yasunori Sato; Koichi Tsuneyama; Joji Haratake; Hiroshi Kurumaya; Kazuyoshi Katayanagi; Shinji Masuda; Hideki Niwa; Hideo Morimoto; Atsuo Miwa; Akio Uchiyama; Bernard C Portmann; Yasuni Nakanuma
Journal:  Am J Surg Pathol       Date:  2004-09       Impact factor: 6.394

9.  Prevalence and distribution of extrapancreatic lesions complicating autoimmune pancreatitis.

Authors:  Hideaki Hamano; Norikazu Arakura; Takashi Muraki; Yayoi Ozaki; Kendo Kiyosawa; Shigeyuki Kawa
Journal:  J Gastroenterol       Date:  2007-02-06       Impact factor: 7.527

10.  Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis.

Authors:  Mark Topazian; Thomas E Witzig; Thomas C Smyrk; Jose S Pulido; Michael J Levy; Patrick S Kamath; Suresh T Chari
Journal:  Clin Gastroenterol Hepatol       Date:  2008-03       Impact factor: 11.382

View more
  31 in total

1.  What is the current role of endoscopy in primary sclerosing cholangitis?

Authors:  Benjamin Tharian; Nayana Elizabeth George; Tony Chiew Keong Tham
Journal:  World J Gastrointest Endosc       Date:  2015-08-10

Review 2.  Adult bile duct strictures: differentiating benign biliary stenosis from cholangiocarcinoma.

Authors:  Hiep Nguyen Canh; Kenichi Harada
Journal:  Med Mol Morphol       Date:  2016-06-27       Impact factor: 2.309

3.  First case of IgG4-related sclerosing cholangitis associated with autoimmune hemolytic anemia.

Authors:  Hironori Masutani; Kosuke Okuwaki; Mitsuhiro Kida; Hiroshi Yamauchi; Hiroshi Imaizumi; Shiro Miyazawa; Tomohisa Iwai; Miyoko Takezawa; Wasaburo Koizumi
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 4.  IgG4-related disease: a new kid on the block or an old aquaintance?

Authors:  Georg Beyer; Theresa Schwaiger; Markus M Lerch; Julia Mayerle
Journal:  United European Gastroenterol J       Date:  2014-06       Impact factor: 4.623

Review 5.  Benign Biliary Strictures.

Authors:  Ashley Altman; Steven M Zangan
Journal:  Semin Intervent Radiol       Date:  2016-12       Impact factor: 1.513

6.  The 2016 diagnostic criteria for primary sclerosing cholangitis.

Authors:  Takahiro Nakazawa; Kenji Notohara; Susumu Tazuma; Atsushi Tanaka; Hiroyuki Isayama; Toshio Tsuyuguchi; Toshiyuki Mori; Hajime Takikawa
Journal:  J Gastroenterol       Date:  2016-12-05       Impact factor: 7.527

7.  Non-MalIg(G4)nant Biliary Obstruction: When the Pill Is Mightier than the Knife.

Authors:  Monica M Dua; Motaz Qadan; Glen A Lutchman; Walter G Park; George Triadafilopoulos; Brendan C Visser
Journal:  Dig Dis Sci       Date:  2014-08-20       Impact factor: 3.199

8.  Two cases of immunoglobulin G4-related sclerosing cholangitis in which transabdominal ultrasonography was useful in diagnosis and follow-up observation.

Authors:  Ikuhiro Kobori; Toshikuni Suda; Akihiro Nakamoto; Hiroki Saito; Osamu Okawa; Rion Sudo; Yoshinori Gyotoku; Yasumi Katayama; Masaya Tamano
Journal:  J Med Ultrason (2001)       Date:  2015-10-14       Impact factor: 1.314

9.  A special subtype of POEMS syndrome: IgG4 subtype.

Authors:  Miao Zheng; Pan Zhou; Kai Zheng; Li Meng; Xian Liu; Mengdi Chu; Jie Lu; Lingli Dong
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

Review 10.  IgG4-related hepatobiliary disease: an overview.

Authors:  Emma L Culver; Roger W Chapman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-14       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.